生物来源
mouse
质量水平
抗体形式
purified antibody
抗体产品类型
primary antibodies
克隆
42-5D11, monoclonal
表单
liquid
包含
≤0.1% sodium azide as preservative
种属反应性
bovine, rat, mouse, human
制造商/商品名称
Calbiochem®
储存条件
OK to freeze
avoid repeated freeze/thaw cycles
dilution
(Frozen Sections
Immunoblotting (1 µg/mL)
Paraffin Sections )
同位素/亚型
IgG1
运输
wet ice
储存温度
−20°C
靶向翻译后修饰
unmodified
基因信息
human ... MMP2(4313)
一般描述
Purified mouse monoclonal antibody (see application references). Recognizes the ~72 kDa latent and the ~66 kDa active forms of MMP-2.
Recognizes the ~72 kDa latent and the ~66 kDa active forms of the MMP-2.
This Anti-MMP-2 (Ab-3) Mouse mAb (42-5D11) is validated for use in Frozen Sections, Immunoblotting, Paraffin Sections for the detection of MMP-2 (Ab-3).
免疫原
Epitope: within amino acids 468-483 of human MMP-2 (numbered from the propeptide)
Human
a synthetic peptide (VTPRDKPMGPLLVATF) corresponding to amino acids 468-483 of human MMP-2
应用
Frozen Sections (see application references)
Immunoblotting (1 g/ml)
Paraffin Sections (see application references)
包装
Please refer to vial label for lot-specific concentration.
外形
In 100 mM sodium phosphate buffer, 0.1% BSA, pH 7.0
制备说明
Following initial thaw, aliquot and freeze (-20°C).
分析说明
Negative Control
MMP-9 protein (Cat. Nos. PF024 or PF038)
MMP-9 protein (Cat. Nos. PF024 or PF038)
Positive Control
MMP-2 protein (Cat. Nos. PF023 or PF037)
MMP-2 protein (Cat. Nos. PF023 or PF037)
其他说明
Cottam, D. W. and Rees, R. C. 1993. Intl J. Oncol.2, 861.
Fujimoto, N., et al. 1993. Clinica Chimica Acta.221, 91.
Stetler-Stevenson, W. G., et al. 1993. FASEB J.7, 1434.
Woessner, J. F. 1991. FASEB J.5, 2145.
Liotta, L. A. and Stetler-Stevenson, W. G. 1990. in Seminars in Cancer Biology, ed. M. M. Gottesman. Vol. 1(2), 99.
Fujimoto, N., et al. 1993. Clinica Chimica Acta.221, 91.
Stetler-Stevenson, W. G., et al. 1993. FASEB J.7, 1434.
Woessner, J. F. 1991. FASEB J.5, 2145.
Liotta, L. A. and Stetler-Stevenson, W. G. 1990. in Seminars in Cancer Biology, ed. M. M. Gottesman. Vol. 1(2), 99.
This antibody will not cross-react with human MMP-1, MMP-3, MMP-9, or MMP-13. Antibody should be titrated for optimal results in individual systems.
法律信息
Manufactured by Daiichi Fine Chemical Co., Ltd. Not available for sale in Japan.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
免责声明
Toxicity: Standard Handling (A)
未找到合适的产品？
试试我们的产品选型工具.
储存分类代码
10 - Combustible liquids
WGK
WGK 1
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Laura S Spruill et al.
American journal of physiology. Cell physiology, 293(4), C1362-C1373 (2007-08-03)
Past studies have identified that a unique type of matrix metalloproteinase, the membrane-type-1 MMP (MT1-MMP), is increased within the left ventricle (LV) of patients with dilated cardiomyopathy (DCM). However, the cellular and molecular basis for this induction of MT1-MMP with
Jeffrey A Jones et al.
American journal of physiology. Heart and circulatory physiology, 299(1), H114-H124 (2010-04-27)
Thoracic aortic aneurysms (TAAs) develop as a result of dysregulated extracellular matrix remodeling mediated by several matrix metalloproteinases (MMPs). Membrane type-1 MMP (MT1-MMP) is the prototypical member of a unique family of membrane-bound MMPs, possessing multiple substrates and functions. The
Peter McCluskey et al.
Investigative ophthalmology & visual science, 50(5), 2161-2164 (2009-01-02)
To determine whether MMPs and TIMPs are present in the bleb wall of Molteno implants. An observational case series consisting of ocular specimens from 10 human eyes obtained postmortem from patients who had undergone placement of Molteno implants for glaucoma.
Joseph C Chen et al.
Reproduction (Cambridge, England), 141(5), 675-683 (2011-02-15)
Lactocrine communication of milk-borne bioactive factors (MbFs) from mother to offspring through nursing can affect neonatal development with lasting consequences. Relaxin (RLX), a lactocrine-active peptide found in porcine colostrum, stimulates estrogen receptor-α (ESR1) expression required for uterine development shortly after
Han-Sen Chen et al.
CNS neuroscience & therapeutics, 21(7), 585-590 (2015-05-23)
Hemorrhagic transformation (HT) is a major complication of delayed tissue plasminogen activator (t-PA) treatment in ischemic stroke. We aimed to explore whether peroxynitrite decomposition catalyst (PDC) could prevent such complication. Male Sprague-Dawley (SD) rats were subjected to middle cerebral artery
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持